Meta-regression:
Due to the high heterogeneity found in the analyses, a meta-regression analysis was conducted. A meta-regression revealed a statistically significant association between early gestational age at initiation of pravastatin treatment and decreased risk for the development of preeclampsia (R2=1) and NICU admission (R2=0.33). Statistically significant associations were not found between higher pravastatin dose to prolongation of pregnancy from study entry to delivery, birth weight, perinatal death or NICU admission. Statistically significant associations were not found between earlier gestational age at initiation of pravastatin treatment to prolongation of pregnancy from study entry to delivery, birth weight or perinatal death (Figure S4-S13).